hydroxychloroquine has been researched along with Embryopathies in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Excerpt | Relevance | Reference |
---|---|---|
"Hydroxychloroquine (HCQ), an orally administered Toll-like receptor antagonist widely used in lupus including during pregnancy, was evaluated for efficacy in reducing the historical 18% recurrence rate of CHB." | 5.34 | Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. ( Buyon, JP; Clancy, R; Cohen, RE; Copel, JA; Costedoat-Chalumeau, N; Cuneo, BF; Friedman, DM; Izmirly, P; Kim, M; Masson, M; Phoon, CKL; Robins, K; Saxena, A; Wainwright, BJ; Zahr, N, 2020) |
"In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome." | 2.44 | [Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 1 (25.00) | 2.80 |
Authors | Studies |
---|---|
Izmirly, P | 1 |
Kim, M | 1 |
Friedman, DM | 1 |
Costedoat-Chalumeau, N | 1 |
Clancy, R | 1 |
Copel, JA | 1 |
Phoon, CKL | 1 |
Cuneo, BF | 1 |
Cohen, RE | 1 |
Robins, K | 1 |
Masson, M | 1 |
Wainwright, BJ | 1 |
Zahr, N | 1 |
Saxena, A | 1 |
Buyon, JP | 1 |
Gupta, R | 1 |
High, WA | 1 |
Butler, D | 1 |
Murase, JE | 1 |
Bérezné, A | 1 |
Mouthon, L | 1 |
Petri, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Preventive Approach to Congenital Heart Block With Hydroxychloroquine[NCT01379573] | Phase 2 | 74 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT01379573)
Timeframe: At birth (approximately 9 months)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
a) shortening fraction <28% = 2 SD below normal mean or qualitatively reduced systolic function; b) cardio-thoracic ratio >0.33; c) hydropic changes; d) moderate/severe tricuspid regurgitation. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
(NCT01379573)
Timeframe: At birth (approximately 9 months)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 1 |
(NCT01379573)
Timeframe: Up to 15 months (at birth - 9 months, and 6 months thereafter)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 4 |
(see title) (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
"An autopsy with full evaluation of the heart will be encouraged but cannot be mandated. If AV block or evidence of a cardiomyopathy can be proven, then these will provide the basis for final categorization. If not possible, the death will not be considered a recurrence rate but will be reported." (NCT01379573)
Timeframe: Up to 9 months
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
(gestational age <37 weeks at birth) (NCT01379573)
Timeframe: At birth (approximately 9 months)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 9 |
EKG at birth must confirm 1st degree AV block. It is also possible that a fetus developing 1st degree block on study medication might have developed more advanced block in the absence of study medication. (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 0 |
Echocardiogram reveals 2nd or 3rd degree AV block (NCT01379573)
Timeframe: After enrollment at 16-18 weeks gestation, then weekly until 26 weeks, biweekly to 34 weeks, at birth (approximately 9 months), and at one year follow up (approximately 21 months from enrollment)
Intervention | Participants (Count of Participants) |
---|---|
Pregnant Women With Previous Child With Cardiac Neonatal Lupus | 5 |
2 reviews available for hydroxychloroquine and Embryopathies
Article | Year |
---|---|
[Pregnancy in systemic sclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr | 2008 |
Immunosuppressive drug use in pregnancy.
Topics: Adrenal Cortex Hormones; Azathioprine; Breast Feeding; Cyclophosphamide; Cyclosporine; Female; Fetal | 2003 |
1 trial available for hydroxychloroquine and Embryopathies
Article | Year |
---|---|
Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.
Topics: Administration, Oral; Adult; Autoantibodies; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fe | 2020 |
1 other study available for hydroxychloroquine and Embryopathies
Article | Year |
---|---|
Medicolegal aspects of prescribing dermatological medications in pregnancy.
Topics: Acne Vulgaris; Alopecia; Dermatitis, Atopic; Dermatologic Agents; Dermatology; Female; Fetal Disease | 2013 |